MONITORING TREATMENT OF HISTIOCYTOSIS WITH VEMURAFENIB AND DABRAFENIB

摘要

Provided are methods of determining the amount of a BRAF V600E mutation over time in a subject with Langerhans Cell Histiocytosis (LCH) or Erdheim-Chester Disease (ECD) who is being treated with vemurafenib or dabrafenib.